Sign In
Buy CERT
$5.60
-0.0200 (-0.356%)
At Close: Jun 03, 2026
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
02:08pm, Monday, 14'th Apr 2025
Certara, Inc. CERT on Monday announced expected revenue and bookings for the first quarter.
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing
08:15am, Monday, 14'th Apr 2025
RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution des
Buy Certara After The FDA Announcement
01:15pm, Friday, 11'th Apr 2025
The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, wit
Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock?
11:05am, Friday, 11'th Apr 2025
Certara (CERT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
10:44am, Friday, 11'th Apr 2025
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Certara price target raised by $4 at Baird, here's why
08:15am, Friday, 11'th Apr 2025
21 May
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
08:00am, Tuesday, 01'st Apr 2025
RADNOR, Pa., April 01, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has released a new version of the Simcyp™ Simulator for physiologic
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
04:15pm, Wednesday, 05'th Mar 2025
RADNOR, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Adrian McKemey, Ph.D.
Certara, Inc. (CERT) Q4 2024 Earnings Call Transcript
08:03pm, Wednesday, 26'th Feb 2025
Certara, Inc. (NASDAQ:CERT ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executi
Certara, Inc. (CERT) Surpasses Q4 Earnings and Revenue Estimates
07:45pm, Wednesday, 26'th Feb 2025
Certara, Inc. (CERT) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.09 per share a year ago.
Certara Reports Fourth Quarter 2024 Financial Results
04:15pm, Wednesday, 26'th Feb 2025
RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the fourth quarter and full ye
RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth q
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
07:55am, Wednesday, 15'th Jan 2025
Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million Confirms Adjusted EBITDA within Guidance Range of $120 million to $124 million
Final Trade: CERT, XLE, DAL, OKTA
07:14pm, Friday, 10'th Jan 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
04:15pm, Thursday, 02'nd Jan 2025
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd An
